Posted on

Nova Mentis Uncovers Diagnostic Biomarkers in Preclinical Autism Study

December 8, 2020 8:12 am Published by 

Novamentis

Vancouver, British Columbia – December 8, 2020 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) (“NOVA” or the “Company”) is pleased to announce that it has uncovered molecular and bacteriologic diagnostic markers in its recently completed preclinical model study of autism spectrum disorder (ASD). This behavioral study, based on prenatal exposure to valproic acid (VPA) in rats, was designed, in conjunction with Dr. Viviana Trezza, Department of Science, Roma Tre University, Rome, Italy, by Pilz Bioscience Corp (Pilz), a wholly-owned subsidiary of NOVA.

“We have identified quantifiable changes in levels of inflammatory cytokines and bacteria in ASD animals that will hopefully allow us to establish subsets of specific treatable disorders within the ‘spectrum’ called autism”, stated Marvin S. Hausman MD, CMO of Pilz.

“These baseline levels of objective biomarkers will be used to substantiate behavioral responses within the ASD animals that will be treated with our proprietary psilocybin drug in a study scheduled to begin in January 2021,” added Dr. Hausman. “NOVA is establishing itself as a leader in the development of objective biologic endpoints to validate subjective behavioral changes in people receiving psychedelic therapy.”

The background to Pilz selecting the VPA ASD behavioral rat model was based on several facts. ASD is a developmental disorder whose main features are impairments in social interaction and verbal and non-verbal communication, together with stereotyped patterns of behavior. Despite scientific and clinical studies to date, the causes of ASD are still unknown. What is known is that human prenatal exposure to the drug valproate (VPA) is associated with increased risk of neurodevelopmental problems, cognitive deficits, and autism in children.

Dr. Trezza has shown that “a single prenatal injection of VPA in rodents results in behavioral impairments resembling the core signs of ASD, supporting the high face validity for prenatal VPA as an animal model of autism.” – Tartaglione, 2019(1). Several other research groups confirm these findings.

Another reason for using this model is Pilz’s scientific premise that the autism pathway induced by VPA may involve similar factors causing other chronic human diseases, including genetic, environmental chemicals, infections, neuroinflammation (oxidative stress), immune system dysfunction and alterations in the microbiome.

The scientists at Pilz have designed a novel diagnostic paradigm of ASD causation measuring levels of inflammatory molecules, called cytokines, and specific bacteriologic taxa and species within blood and fecal samples.

The data is undergoing analysis by Dr. Kyle H. Ambert, a recently engaged consultant for the program. Dr. Ambert is currently Director of Data Science at Nike, Inc., and has extensive experience in data analytics, machine learning, artificial intelligence, and applied analytics.  His previous experience includes postings with the National Library of Medicine and Intel Corp.  Dr. Ambert holds a PhD in Biomedical Informatics from Oregon Health & Science University.

“I am excited about my relationship with Pilz Bioscience Corp. and the results and progress to date using the VPA rat model that we have validated in our lab,” said Dr. Trezza. “I look forward to the upcoming treatment phase of the program and hope that we will establish therapeutic levels of the Pilz psilocybin drug that have application to the treatment of ASD patients.”
References:

(1) Tartaglione, A.T., Schiavi, S., Calamandrei, G. and Trezza, V. 2019. Prenatal valproate in rodents as a tool to understand the neural underpinnings of social dysfunctions in autism spectrum disorder. Neuropharmacology 159,107477.

About Nova Mentis Life Science Corp.

Nova Mentis Life Science Corp. is a Canadian-based, public company whose focus is to build and support a diversified portfolio of health and wellness businesses. Key holdings include its wholly-owned subsidiary, Pilz Bioscience Corp., a biotechnology company developing medicinal psychedelics for neuroinflammatory conditions with a significant cognitive component and high unmet therapeutic needs, initially focussed on Autism Spectrum Disorder (ASD). – Nova Mentis Biotech Corp., a R&D driven company focused on exploring the anti-inflammatory effects of psilocybin in underexplored metabolic indications such as obesity and diabetes – Just Kush Enterprises, an Okanagan BC based, Health Canada Standard Licensed facility focused on the cultivation of premium, small batch Kush dominant cultivars.

For further information on the Company, please visit https://www.novamentis.ca or email info@novamentis.ca.

On Behalf of the Board

Will Rascan, President & CEO
Nova Mentis Life Science Corp.

Phone: 778-819-0244
Toll Free: 1-833-542-5323
Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains statements that constitute “forward-looking statements.” Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur.

Posted on

Health Crisis-Induced Post-Traumatic Stress Disorder Creates Growing Need for Treatment Options

NEW YORK, Dec. 8, 2020 /PRNewswire/ — The health crisis has resulted in over one million deaths to date, but another emerging consequence of the global pandemic is affecting a much larger demographic. Aside from the growing death toll, the COVID-19 pandemic is sending mental illness cases skyrocketing, including an increase in post-traumatic stress disorder (PTSD). An estimated 70% of US adults experience at least one trauma in their lives that could lead to PTSD, yet effective treatments are few and far between. At present there are only five FDA-approved prescription drugs for the treatment of PTSD, including Pfizer’s (NYSE: PFE) Zoloft. There are also off label treatments like AstraZeneca’s (NASDAQ: AZN) Quetiapine. The problem is that these medications can be highly addictive and often come with a long list of side effects, fueling companies like Tonix Pharmaceuticals (NASDAQ: TNXP), Mind Medicine (MindMed) Inc. (NEO: MMED) (OTCQB: MMEDF), and Mydecine Innovations Group Inc. (CSE: MYCO) (MYCOF) to develop effective alternatives.

Mydecine Innovations Group is an emerging biopharma and life sciences company focused on the research, development, and acceptance of alternative nature-sourced medicine to help combat the growing mental health crisis.

Pandemic Shines Light on Demand for Effective PTSD Treatments

The mental health of first responders became a major focus following the aftermath of the 9/11 terrorist attacks, shedding light on the risks of being exposed to emergency settings. Frontline workers are being tested to their limits once again due to COVID-19 and are at a high risk of developing PTSD.

While many biotech companies have switched gears to focus on potential vaccines and treatments for COVID-19, Mydecine Innovations Group is looking to help tackle the ongoing mental health crisis through its clinical trials and its own digital mental health platform. In mid-November, Mydecine announced the international expansion of its Phase 2A clinical trials of psilocybin-assisted psychotherapy to treat chronic PTSD in veterans and emergency medical services (EMS) personnel.

The research is taking place at Leiden University Medical Centre in the Netherlands, the University of Alberta, and the University of Western Ontario, with plans to add additional clinical sites in the USA, Europe, and Australia. The clinical trials will explore how the brain responds to psychedelics to develop a better understanding of the biological underpinnings of the experience. Following their completion, Mydecine Innovations Group will use the data from their studies to build on its knowledge to move forward with an application for FDA breakthrough designation.

Mydecine Innovations Group also recently launched the Mindleap app, the world’s first telehealth platform for psychedelic integration. The platform, which was launched on September 30 on iOS and Android, offers a powerful set of tools for managing mental healthcare. Mindleap allows users to connect virtually with specialists and enables mood, emotion, and habit tracking, while having the ability to schedule appointments, and purchase mental health services.

Before the new year, Mydecine Innovations Group will be expanding Mindleap by adding mental health specialists with different aptitudes and a digital therapeutics marketplace that offers comprehensive mental health programs that focus on addiction, meditation, psychedelic integration, holistic wellness, and drug harm reduction.

Psychedelic medicine biotech company Mind Medicine (MindMed) Inc. (NEO: MMED) (OTCQB: MMEDF) is another company making headway in its clinical studies to evaluate potential treatments to help patients with anxiety, ADHD, cluster headaches, and substance abuse. MindMed is also in the process of establishing a digital medical division known as Albert, an integrated technical platform and comprehensive toolset aimed at delivering psychedelic-inspired medicines and experiential therapies combined with digital therapeutics.

Tonix Pharmaceuticals (NASDAQ: TNXP) is another biopharmaceutical company looking to help combat mental illness, although the company hit a speedbump in its Phase III RECOVERY study of Tonmya for PTSD earlier this year. In February, Tonix decided to stop enrollment in the study due to inadequate separation from placebo. Luckily, the company continued forward and has recently outlined a new statistical method to analyze future PTSD drug studies.

Until these alternative treatments come to market, consumers are continuing to turn to Pfizer’s (NYSE: PFE) Zoloft to combat things like depression, anxiety, and PTSD. In fact, Zoloft is one of the most commonly prescribed antidepressants in the US and in other countries, which led to a shortage of the drug during the height of the pandemic.

Another treatment for PTSD and other mental illnesses, including schizophrenia and bipolar disorder, is the powerful antipsychotic quetiapine, which was developed by AstraZeneca (NASDAQ: AZN) and is sold under the name Seroquel. The drug has become wildly popular for several off label uses, including insomnia caused by PTSD; however, the adverse effects of the drug came into the spotlight through data obtained from the FDA’s Adverse Event Reporting System in 2017.

Of course, Seroquel isn’t the only prescription antidepressant that causes adverse effects. Prescription drugs for depression, anxiety, and PTSD all come with a list of common and severe side effects, which range from nausea and dizziness to loss of consciousness and suicidal ideation.

The market is clearly in need of safe and effective alternatives for treating mental health, creating a large opportunity for companies like Mydecine Innovations Group.

For more information on Mydecine Innovations Group (CSE: MYCO) (MYCOF), please visit this link.

Disclaimer:  Microsmallcap.com (MSC) is the source of the Article and content set forth above. MSC owns and operates Streetsignals.com. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MSC or any company mentioned herein. The commentary, views and opinions expressed in this release by MSC are solely those of MSC and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MSC and FNM for any investment decisions by their readers or subscribers. MSC and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author (MSC), and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author (MSC) has not independently verified or otherwise investigated all such information. None of the Author, MSC, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment. FNM was not compensated by any public company mentioned herein to disseminate this press release but was compensated twenty five hundred dollars by MSC, a non-affiliated third party to distribute this release on behalf of Mydecine Innovations Group Inc.

FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MSC and FNM undertake no obligation to update such statements.

‍

Posted on

Mydecine Innovations Group to Make First Commercial Export of Legal Psilocybin Mushrooms

DENVER, Dec. 08, 2020 (GLOBE NEWSWIRE) — Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced that it has completed its first commercial harvest of 20 kilograms of psilocybin mushrooms at its research and cultivation facility in Jamaica. The Company is now preparing to export the harvest to its Canadian cGMP Facility which has a Health Canada schedule 1 Dealer’s License attached to it, allowing for legal import.

“We are pleased to announce the completion of our first commercial harvest of natural psilocybin mushrooms,” said Joshua Bartch, CEO and Chairman of Mydecine. “There is more research needed on these compounds in order to better understand the entourage effect experienced by patients which has shown dramatically effective results compared to single-molecule synthetic psilocybin in preliminary studies. As the industry grows, the need for naturally occurring psilocybin and access to large quantities of these molecules will be paramount and we are excited to be the first to advance this movement at scale.”

Once received by the Company’s facility in Canada, the psilocybin mushrooms will be extracted, refined and turned into a cGMP final product for controlled therapeutic purposes. Mydecine’s final product be made available for purchase by other licensed institutions and companies conducting clinical research into the efficacy of these compounds to treat various health conditions including anxiety, addiction, depression and PTSD. Portions of the harvest will also be used for Mydecine’s proprietary genetic, pharmacology, and clinical research. The clinical use will be for the studies and developing protocols of psilocybin-assisted psychotherapy to treat PTSD in veterans and other frontline workers.

About Mydecine Innovations Group
Mydecine Innovations Group™ is a life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing wellbeing. The company’s world-renowned medical and scientific advisory board is progressing a robust R&D pipeline of psychedelic derived therapeutics, novel compounds, therapies, and controlled drug delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, extract, and analyze natural and synthetic psychedelic compounds with full government approval through Health Canada.

‍

Posted on

HAVN LIFE SCIENCES TO SUPPLY PSYCHEDELIC COMPOUNDS TO CLINICAL STUDIES FOCUSED ON VETERANS AND PTSD

Havn Life will collaborate on future clinical studies in the U.S. and Canada with Heroic Hearts to investigate effects of low-dosage psychoactive compounds on veterans the post-traumatic stress disorder (PTSD).

Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”), a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural healthcare products, and innovative mental health treatment to support brain health and enhance the capabilities of the mind, is pleased to announce it has signed a Memorandum of Agreement (“MOA”) with the international veterans organization, Heroic Hearts Project (“Heroic Hearts”).

Heroic Hearts is a registered 501(c)(3) non profit organization in the United States that connects military veterans struggling with mental trauma, to psychedelic therapy options including ayahuasca, psilocybin, and ketamine. Heroic Hearts also provides support and professional counseling to these veterans throughout the process. These veterans typically have tried all the available resources offered by the Department of Veteran Affairs with limited success leaving them with very few options.

“This collaboration between Havn Life and Heroic Hearts has the potential to make an extraordinary impact of the mental health and wellness of military veterans,” said Susan Chapelle, EVP of Research and Development at Havn Life. “Under the agreement, Havn Life will supply products and compounds to be used in Heroic Hearts’ future clinical studies that will investigate the effects of low-dosage psychedelic compounds on veterans suffering from emotional trauma and PTSD. This progressive research will help develop clinical trial formulations to aid in the recovery of PTSD and other trauma-related disorders. We look forward to working closely with veterans and others with military backgrounds.”

Heroic Hearts is also working to advance the body of scientific evidence around psychedelic compounds through approved research studies with the University of Georgia and the University of Colorado Boulder.

“We are laying the groundwork to lead  standardization of the psychedelic supply chain and the development of IP while also contributing to the limited research on PTSD, human performance optimization and cutting-edge mental health paradigms” Chapelle added.

Two-thirds of Canadian military personnel with PTSD do not respond completely to the best available evidence-based therapies, according to a 2018 study that examined recovery, rehabilitation and reintegration of injured service members and veterans. Further, suicide risk is higher in Canadian Armed Forces (CAF) Veterans than the Canadian general population, found a “Life After Service” study published in 2016.

As part of the agreement, Havn Life will supply products for any future U.S. and Canadian studies, upon approval of  its Licensed Dealer application. Havn Life scientists will provide support for Heroic Heart’s current studies and aid in the development of research protocols. The collaboration will also explore the use of mental health and pharmacology management platforms to collect baseline and usage data from veterans.

Havn Life is also providing funding to launch a Heroic Hearts division in Canada, to help expand support to Canadian Veterans.

On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer

About Havn Life Sciences Inc.

Havn Life Sciences is a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural healthcare products, and innovative mental health treatment to support brain health and enhance the capabilities of the mind. Learn more at: havnlife.com and follow us on Facebook, Twitter and Instagram.

Connect

Investor Relations
ir@havnlife.com
604 (687)-7130

Facebook: @havnlife
Twitter: @havnlife
Insta: @havn.life
LinkedIn: @Havn Life

Media Contact
Brittany@exvera.com
778-238-6096

Posted on

MindMed Files Final Prospectus In Connection With Bought Deal Equity Financing

Financing To Support The Development Of MindMed’s Digital Medicine Division And Psychedelic Inspired Medicines And Experiential Therapies

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

TORONTO, Dec. 8, 2020 /CNW/ — Mind Medicine (MindMed) Inc. (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ) (“MindMed” or the “Company“) is pleased to announce that further to its previously announced offering (the “Offering“), it has filed a final short form prospectus (the “Prospectus“) with the securities commissions or similar authorities in each province of Canada, other than Québec. Pursuant to the underwriting agreement among the Company, Canaccord Genuity Corp. (the “Lead Underwriter“) and Eight Capital (together with the Lead Underwriter, the “Underwriters“), the Underwriters have agreed to purchase 15,800,000 units of the Company (the “Units“), on a “bought deal” basis, at a price per Unit of $1.90 (the “Issue Price“) for gross proceeds of $30,020,000.

The Company has also granted the Underwriters an over-allotment option to purchase up to an additional 15% of the Units at the Issue Price, exercisable in whole or in part, at any time on or prior to the date that is 30 days following the closing of the Offering. If this option is exercised in full, an additional $4,503,000 will be raised pursuant to the Offering and the aggregate proceeds of the Offering will be $34,523,000.

Each Unit will be comprised of one subordinate voting share of the Company (each, a “Subordinate Voting Share“) and one-half of one Subordinate Voting Share purchase warrant (each whole warrant, a “Warrant“). Each Warrant shall entitle the holder thereof to purchase one Subordinate Voting Share at an exercise price of $2.45, for a period of 36 months following the closing of the Offering. If, at any time following the closing of the Offering, the daily volume weighted average trading price of the Subordinate Voting Shares on the NEO Exchange Inc. is greater than $4.00 per Subordinate Voting Share for the preceding 10 consecutive trading days, the Company may, upon providing written notice to the holders of Warrants, accelerate the expiry date of the Warrants to the date that is at least 30 days following the date of such written notice.

The Company intends to use the net proceeds of the Offering for investment in its digital medicine division, additional microdosing research and development as well as general working capital and corporate purposes, including to further fund its ongoing programs.

The Offering is scheduled to close on or about December 11, 2020 and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.

The Prospectus containing important information relating to these securities has been filed with securities commissions or similar authorities in each province of Canada, other than Québec and may be subject to amendment. A copy of the Prospectus can be obtained under the Company’s corporate profile on SEDAR at www.sedar.com.

About MindMed

MindMed is a psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines and experiential therapies to address addiction and mental illness. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed team brings extensive biopharmaceutical experience to the Company’s groundbreaking approach to developing the next generation of psychedelic inspired medicines and experiential therapies.

MindMed trades on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in the United States under the symbol MMEDF and in Germany under the symbol MMQ. For more information: http://www.mindmed.co/

Forward-Looking Statements

Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the closing of the Offering, regulatory approvals and the intended use of proceeds of the Offering. There are numerous risks and uncertainties that could cause actual results and MindMed’s plans and objectives to differ materially from those expressed in the forward-looking information. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

Posted on

CHAMPIGNON BRANDS APPOINTS CHRISTOPHER HOBBS AS INTERIM CHIEF FINANCIAL OFFICER

VANCOUVER, BRITISH COLUMBIA (December 8, 2020) – Champignon Brands Inc. (the “Company”), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), today announced that Christopher Hobbs will join the Company as Interim Chief Financial Officer (CFO), effective December 8, 2020. Stephen Brohman, the Company’s current contract CFO, has resigned from the position, effective December 7, 2020.

Mr. Brohman has agreed to assist the Company in order to ensure a smooth transition to a new fulltime CFO and the company appreciates Mr. Brohman’s cooperation in that regard.

Mr. Hobbs’ appointment is pending the recruitment and appointment of a full-time CFO as the Company announced on November 24, 2020.

Christopher Hobbs has acted as CFO for several public and private companies operating in the resource, health sciences and technology sectors. Mr. Hobbs is a member of the Chartered Accountants of Ontario and holds a Bachelor of Business Administration Degree from the Schulich School of Business at York University.

Dr. Roger McIntyre, Chief Executive Officer, Champignon Brands said, “Chris brings a depth of experience and expertise relevant to Champignon Brands at this critical time.”

Mr. Hobbs acknowledged Champignon Brands goal to become a global leader in breakthrough treatment for depression and other mental health conditions, noting “the priority now is to work diligently to complete the BCSC continuous disclosure review.”

Champignon Brands Inc. (https://braxiascientific.com) is a research-driven Company specializing in breakthrough ketamine treatment for depression, and other mental health conditions and its suicidal implications as well as delivery platforms for other health products. The Company works closely with subsidiaries that include AltMed Capital Corp. (“AltMed). The Canadian Rapid Treatment Center of Excellence is wholly owned by AltMed.

Investors: info@braxiascientific.com
Media: Victoria Ollers, vollers@rogers.com, 416 822-2288

Posted on

PharmaTher Files FDA Pre-IND Meeting Request for Ketamine in Parkinson’s Disease

TORONTO, Dec. 08, 2020 (GLOBE NEWSWIRE) — PharmaTher Inc., (“PharmaTher” or the “Company”), a wholly-owned subsidiary of Newscope Capital Corporation (CSE: PHRM) (OTC Pink: PHRRF) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that it has filed its pre-Investigational New Drug (“pre-IND”) meeting request and complete pre-IND briefing documents with the U.S. Food and Drug Administration (“FDA”) to support the clinical development of ketamine in Parkinson’s disease and to evaluate the proposed Phase 2 clinical study for ketamine in the treatment of levodopa-induced dyskinesia associated with Parkinson’s disease (“LID-PD”).

“We are pleased to have taken this important step in advancing our ketamine program for Parkinson’s disease via the FDA regulatory pathway, which is part of our overall strategy of progressing our novel ketamine prescription-based therapies to treat neurological disorders for FDA approval,” said Fabio Chianelli, CEO of PharmaTher. “We look forward to finalizing our Phase 2 clinical study for ketamine in Parkinson’s disease and leveraging the pre-IND meeting to unlock additional value in our exclusive FDA-based ketamine programs in depression and pain.”

PharmaTher is progressing its patent portfolio of novel ketamine therapies for Parkinson’s disease, depression and pain via the FDA regulatory pathway. The pre-IND meeting will provide valuable information to pave the way for the Company to conduct a Phase 2 clinical study in the U.S.

Results from preclinical data and case studies in Parkinson’s disease patients have shown that low-dose sub-anesthetic ketamine infusion indicates tolerability, safety and the potential of long-term therapeutic benefit to reduce levodopa-induced dyskinesia, improve on time, and reduce depression. 1-5

Ketamine is an FDA-approved drug with a known safety profile. PharmaTher entered into an exclusive license agreement with the University of Arizona to develop and commercialize ketamine in the treatment of Parkinson’s disease and has filed with the FDA to receive orphan drug designation for ketamine in the treatment of LID-PD.

The Company has assembled a prolific scientific and clinical team experienced in Parkinson’s disease, including Dr. Scott Sherman and Dr. Torsten Falk from the University of Arizona, Dr. Alberto Espay from the University of Cincinnati and Dr. Robert Hauser from the University of South Florida.

About Parkinson’s Disease
Parkinson’s Disease is a debilitating disorder that affects over 1 million people in the U.S. and more than 7 million people worldwide. There is currently no cure for Parkinson’s Disease, although some drug combinations are used to treat the disease symptoms. The global Parkinson’s Disease market is expected to grow from USD $5 billion in 2019 to USD $7.5 billion by the end of 2025 6 and it is estimated that the potential market opportunity for LID-PD to be over USD $3 billion in the U.S. alone.

About PharmaTher Inc.
PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (CSE: PHRM) (OTC Pink: PHRRF), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals. PharmaTher repurposes psychedelic pharmaceuticals, such as FDA-approved ketamine and psilocybin, for FDA approval to treat neurological disorders.
​
​Learn more at:  PharmaTher.com and follow us on Twitter, LinkedIn and Facebook.

​For more information, please contact:        
Fabio Chianelli
Chief Executive Officer
PharmaTher Inc.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: www.pharmather.com

​Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement
This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “potential” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Newscope Capital Corporation’s (the “Company) current belief or assumptions as to the outcome and timing of such future events. Forward-looking information in this press release includes information with respect to the development and commercialization of ketamine for neurological disorders, FDA approval, pre-IND meeting, psilocybin and ketamine programs and product developments. Forward-looking information is based on reasonable assumptions that have been made by the Company at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Company’s management’s discussion and analysis for the period of August 30, 2020 (“MD&A”), dated October 1, 2020, which is available on the Company’s profile at www.sedar.com.

This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.

References:

  1. UA Clinical Trial to Repurpose Ketamine for Parkinson’s Patients.
  2. US20190060254A1— Compositions and methods for treating motor disorders.
  3. Bartlett, et al, 2020. Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia. Experimental Neurology. Volume 333.
  4. Bartlett, M.J., Joseph, R.M., LePoidevin, L.M., Parent, K.L., Laude, N.D., Lazarus, L.B., Heien, M.L., Estevez, M., Sherman, S.J., Falk, T., 2016. Long-term effect of sub-anesthetic ketamine in reducing L-DOPA-induced dyskinesias in a preclinical model.
  5. Sherman, S.J., Estevez, M., Magill, A.B., Falk, T., 2016. Case reports showing a long-term effect of subanesthetic ketamine infusion in reducing L-DOPA-induced dyskinesias. Case Rep. Neurol. 8, 53–58.
  6. 360iResearch 2020.
Posted on

Roadman Investments Appoints Pharma-based Executive Shawn Moniz to Board of Directors

VANCOUVER, British Columbia – December 7, 2020 – Roadman Investments Corp. (TSXV:LITT) (FWB:1QD) (OTC:RMANF) (“Roadman Investments” or the “Company“)  a Canadian Venture Capital and Advisory Firm, is pleased to announce that Shawn Moniz has been appointed to the Company’s Board of Directors effective immediately.

Luke Montaine, CEO of Roadman Investments commented, “We are excited to have Shawn Moniz join our Board of Directors, and look forward to integrating his deep knowledge of the pharmaceutical industry into our roadmap for the Company.  His extensive knowledge of the US and Canadian pharmaceutical space in regards to marketing strategies, product development and consumer behavioural analysis will go a long way in adding to our initiatives for 2021.”

Shawn Moniz commented, “I’m very pleased and excited to have joined the team at Roadman Investments, and I am especially looking forward to working with the Clov BioPharma team.  I see great untapped potential in this company’s ability to productize its Cedar Leaf Oil into the mass production wheel of sanitation products for today’s clean conscience consumer. I look forward to leveraging my experience in working with Dr James Hudson, and the larger team at Roadman”.

Shawn Moniz

Shawn has worked with the Pharma industry for over 20 years, most recently with Klick Health, Canada Largest Health Sciences Agency.  In his career, Shawn has worked with almost every major player in the Canada and US pharmaceutical Markets developing and strategizing multi-million dollar consumer programs.  Most notably, his career client list includes AstraZeneca, Pfizer, Astellas, Takeda, Navartis, Nova nordisk, Edna, UCB, Shire, Merk, Baxter, and Sanofi.

During his tenure in the pharmaceutical vertical Shawn has helped develop countless product strategies, customer journey programs, media-driven allocation strategies including PPC, DTC and Veeva support programs for Canadian as well as American companies.   These programs spanned over 23 disease states, including biological treatment applications of temperature-sensitive vaccines.

Shawn worked with his clients to develop monetization models for account groups and individual brands.  The evolution of these models are still used by some companies today.  Shawn will be looking to develop and implement such models with the BioPharma and Roadman teams and work hand in hand with the monetization focus of the company for this upcoming quarter, and upcoming fiscal year of planning.

Shawn is currently the CEO of Plant & Co Brands Inc., a public company trading on the Canadian Securities Exchange (“CSE”) under the symbol: VEGN.  Shawn also sits on various technology advisory boards as he continues to be involved in entrepreneur-based initiatives spanning various verticals, pharmaceutical included.

 

In addition, the Company also announces that it will be conducting a private placement financing for gross proceeds of up to $300,000 through the issuance of up to 10,000,000 shares (“Share”) at a price of $0.03 per Share.

 

The securities being offered under the private placement have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

 

About Roadman Investments

Roadman Investments is a Canadian Venture Capital and Advisory Firm that strives to actively drive innovation and accelerate growth within its portfolio holdings. Roadman looks for companies and investments that offer breakthrough products, devices, treatments and health supplements with a focus on health and wellness.

For further information please contact:

Luke Montaine CEO,
Director Roadman Investments Corp.
Luke@roadmancorp.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release contains “forward-looking statements” within the meaning of applicable securities laws. Forward-looking statements can be identified by any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “expects” or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “estimates” or “intends”, or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved), and variations of such words, and similar expressions are not statements of historical fact and may be forward-looking statements. Examples of forward-looking statements include, among others, statements we make about the Company, its subsidiaries or other Company’s that the Company has invested in or is otherwise affiliated with, regarding planned research and development activities, financing arrangements, investment strategies, returns on investments, contractual obligations including but not limited to obligations to purchase materials or meet sales milestones, strategy for customer retention, growth, product development, market position, financial results and reserves, other statements relating to the financial and business prospects, management’s ability it identify and evaluate investments, management’s ability to obtain the necessary funding or obtain the necessary licenses and approvals to operate, specifically, the necessary licenses and approvals to open any such facilities in California or the United States of America.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: economic and financial conditions, including volatility in interest and exchange rates, commodity and equity prices and the value of financial assets, continued volatility in the capital or credit markets the adequacy of our cash flow to fund the operations of the Company or its affiliates, strategic actions, including acquisitions and dispositions and our success in evaluating acquired businesses and our success in developing the businesses underlying these acquisitions, the occurrence of hostilities, political instability or catastrophic events, changes in customer demand, the extent to which we are successful in gaining new long-term relationships with customers or retaining existing ones and the level of service failures that could lead customers to use competitors’ services, developments and changes in laws and regulations, including increased regulation of the medical, health and wellness industries through legislative action and revised rules and standards applied by the international medical, pharmaceutical, health and wellness regulatory bodies, changes in the price of inventory and other key materials and disruptions in supply chains for these materials, closures or slowdowns and changes in contracted service provider costs and labor difficulties, including stoppages affecting either our operations or our service providers abilities to conduct research and develop and produce products, management’s ability to operate our business models, availability of financing to provide sufficient working capital maintain the business as a going concern, availability of financing to fund the Company’s or it is subsidiaries business operations, including but not limited to, meeting the Company’s obligations under the agreement with Psychedelic insights, compliance and approvals under the appropriate State and Federal laws and other factors as discussed in the Company’s filings with Canadian securities regulators, which are available at www.sedar.com. Investors are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements. The forward-looking statements included in this news release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities legislation. This news is not for dissemination in the United States of America.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Posted on

Numinus Wellness Inc. Announces $10 Million Bought Deal Public Offering

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

VANCOUVER, BC, Dec. 7, 2020 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. and Eight Capital (the “Underwriters”). The Underwriters have agreed to purchase, on a bought deal basis pursuant to the filing of a short form prospectus, an aggregate of 14,706,000 units (the “Units”) at a price of $0.68 per Unit (the “Offering Price”) for aggregate gross proceeds to the Company of approximately $10 million (the “Offering”).

Each Unit shall consist of one common share (each a “Common Share”) and one-half of one common share purchase warrant of the Company (each a “Warrant”). Each Warrant shall be exercisable to acquire one common share of the Company for a period of 24 months from closing of the transaction at an exercise price of C$0.90 per Warrant.

The Company has granted the Underwriters an option (the “Over-Allotment Option”) to purchase up to an additional 2,205,900 Units at a price of C$0.68 per Unit, exercisable at any time, for a period of 30 days after and including the Closing Date, which would result in additional proceeds of approximately $1.5 million. The Over-Allotment Option is exercisable to acquire Units, Common Shares and/or Warrants (or any combination thereof) at the discretion of the Underwriters.

The Units will be offered by way of a short form prospectus to be filed in all provinces of Canada except Quebec. The Offering is expected to close on December 29, 2020 and is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the TSX Venture Exchange (“TSXV”) and the applicable securities regulatory authorities.

The Company will use best efforts to obtain the necessary approvals to list the Common Shares, Warrants, and the Common Shares issuable upon exercise of the Warrants on the TSXV.

Numinus intends to use the proceeds of the Offering to

  • upgrade existing laboratory and equipment to prepare for clinic trials;
  • seek approval for and commence compassionate access trials;
  • review and complete potential acquisitions;
  • facilitate research and development of medical protocols and treatment standard operating procedures for the use of psychedelic therapies;
  • potentially identify and build out a purpose-built facility to complement its existing wellness centre; and
  • general working capital purposes.

ON BEHALF OF THE BOARD OF NUMINUS WELLNESS INC.

Payton Nyquvest

President, Chief Executive Officer and Chair

About Numinus

Numinus Wellness Inc. (TSXV: NUMI) is a mental health and wellness company creating an ecosystem of solutions centred around safe, evidence-based, accessible psychedelic-assisted psychotherapy to help people heal and be well.

Numinus Health is dedicated to delivering innovative treatments to address physical, mental, and emotional health, through clinics and virtual services.

Numinus R&D is conducting implementation science and leveraging partnerships to beta-test and refine optimal models of psychedelic-assisted psychotherapy delivery, setting the stage for approved routine use in mental health and wellness care.

Numinus Bioscience is focused on developing testing methods and effective formulas for the evolving psychedelics space. Health Canada licences, scientific expertise, and new technologies facilitate ongoing innovation, and high-throughput contract services generate established revenue.

Learn more at numinus.ca, and follow us on Facebook, Twitter, and Instagram.

Forward Looking Statements

This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licences and any inability to obtain all necessary governmental approvals licences and permits to operate and expand the Company’s facilities; regulatory or political change such as changes in applicable laws and regulations, including federal and provincial legalization, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; the Company’s limited operating history and lack of historical profits; reliance on management; the Company’s requirements for additional financing, and the effect of capital market conditions and other factors on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with research and development institutions, customers and suppliers. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law. SOURCE Numinus Wellness Inc.

For further information: Dana Harvey, Chief Communications Officer, media@numinus.ca

 

herbal twig
Posted on

Numinus Wellness Inc. Announces an Increase to the Previously Announced Bought Deal Public Offering

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

VANCOUVER, BC, Dec. 7, 2020 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. and Eight Capital (the “Underwriters”) to increase the size of its previously announced bought deal financing. Pursuant to the revised terms of the offering, the Underwriters have agreed to purchase, on a bought deal basis an aggregate of 22,059,000 units (the “Units”) at a price of $0.68 per Unit (the “Offering Price”) for aggregate gross proceeds to the Company of approximately $15 million (the “Offering”).

Each Unit shall consist of one common share (each a “Common Share”) and one-half of one common share purchase warrant of the Company (each a “Warrant”). Each Warrant shall be exercisable to acquire one common share of the Company for a period of 24 months from closing of the transaction at an exercise price of C$0.90 per Warrant.

The Company has granted the Underwriters an option (the “Over-Allotment Option”) to purchase up to an additional 3,308,850 Units at a price of C$0.68 per Unit, exercisable at any time, for a period of 30 days after and including the Closing Date, which would result in additional proceeds of approximately $2.3 million. The Over-Allotment Option is exercisable to acquire Units, Common Shares and/or Warrants (or any combination thereof) at the discretion of the Underwriters.

The Units will be offered by way of a short form prospectus to be filed in all provinces of Canada except Quebec. The Offering is expected to close on December 29, 2020 and is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the TSX Venture Exchange (“TSXV”) and the applicable securities regulatory authorities.

The Company will use best efforts to obtain the necessary approvals to list the Common Shares, Warrants, and the Common Shares issuable upon exercise of the Warrants on the TSXV.

Numinus intends to use the proceeds of the Offering to

  • upgrade existing laboratory and equipment to prepare for clinic trials;
  • seek approval for and commence compassionate access trials;
  • review and complete potential acquisitions;
  • facilitate research and development of medical protocols and treatment standard operating procedures for the use of psychedelic therapies;
  • potentially identify and build out a purpose-built facility to complement its existing wellness centre; and
  • general working capital purposes.

ON BEHALF OF THE BOARD OF NUMINUS WELLNESS INC.

Payton Nyquvest

President, Chief Executive Officer and Chair

About Numinus

Numinus Wellness Inc. (TSXV: NUMI) is a mental health and wellness company creating an ecosystem of solutions centred around safe, evidence-based, accessible psychedelic-assisted psychotherapy to help people heal and be well.

Numinus Health is dedicated to delivering innovative treatments to address physical, mental, and emotional health, through clinics and virtual services.

Numinus R&D is conducting implementation science and leveraging partnerships to beta-test and refine optimal models of psychedelic-assisted psychotherapy delivery, setting the stage for approved routine use in mental health and wellness care.

Numinus Bioscience is focused on developing testing methods and effective formulas for the evolving psychedelics space. Health Canada licences, scientific expertise, and new technologies facilitate ongoing innovation, and high-throughput contract services generate established revenue.

Learn more at numinus.ca, and follow us on Facebook, Twitter, and Instagram.

Forward Looking Statements

This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licences and any inability to obtain all necessary governmental approvals licences and permits to operate and expand the Company’s facilities; regulatory or political change such as changes in applicable laws and regulations, including federal and provincial legalization, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; the Company’s limited operating history and lack of historical profits; reliance on management; the Company’s requirements for additional financing, and the effect of capital market conditions and other factors on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with research and development institutions, customers and suppliers. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law. SOURCE Numinus Wellness Inc.

For further information: Dana Harvey, Chief Communications Officer, media@numinus.ca